FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
This is a summary aggregated from CNBC. Read the complete article on the original site:
Read full article at CNBC
